Beyond research summary
Small fragments. A specific laboratory question.
Fengqin Feng & Yoshinori Mine · 2006 · International Journal of Food Science & Technology
Laboratory · intestinal-cell model
An original Beyond research note—not the original publication, a patient recommendation or an agency endorsement.
The question
Can smaller, phosphorylated fragments of egg-yolk phosvitin change iron uptake in an intestinal-cell model? The question concerns a prepared ingredient under laboratory conditions—not whether an egg, or a finished supplement, improves iron status in people.
How they approached it
The researchers evaluated phosvitin-derived phosphopeptides with iron in a Caco-2 cell monolayer. Caco-2 cells are used to model aspects of the intestinal lining. Changing the peptide concentration lets researchers examine how the formulation environment affects the cellular response.
What was measured?
The reported endpoint was iron uptake in the cell model. It was not the fraction of an oral dose absorbed by a person, a blood ferritin response, or a change in haemoglobin. A cell-level result belongs in the laboratory category of our “What did they measure?” guide.
What the study found
The paper reports increased iron uptake under specified experimental conditions, with findings dependent on phosphopeptide concentration. That is not a general rule that more peptide delivers more iron. The tested preparation, iron conditions and concentration must travel with any interpretation; we do not turn the paper into a universal multiplier.
What we can conclude
This supports investigating processed phosphopeptides as part of an iron-delivery formulation. It also makes a useful distinction: intact phosvitin and its processed fragments are not interchangeable ingredients.
Where the limits sit
An intestinal-cell monolayer does not reproduce a person’s digestion, iron stores, inflammation, whole-body regulation or everyday use. This paper tested neither human absorption nor Beyond Iron+. It cannot establish clinical benefit, long-term tolerability, or an effective consumer dose.
Relevance to Beyond
A hypothesis, read in context.
Beyond is studying phosvitin-derived phosphopeptides, beginning with iron. This publication supplies a preclinical rationale for that hypothesis; product-specific characterization and appropriately designed human studies remain separate work. Our animation illustrates a proposed process, not a measurement from this paper.
Source & bibliography
The original belongs to its publisher.
Feng, F., & Mine, Y. (2006). Phosvitin phosphopeptides increase iron uptake in a Caco-2 cell monolayer model. International Journal of Food Science & Technology, 41(4), 455–458.
DOI: 10.1111/j.1365-2621.2005.01073.x
This page contains Beyond’s original interpretation only. The publication or agency resource is not hosted or reproduced here. Access to the original may depend on the publisher.
Open original study (opens in a new tab)Keep exploring
Different sources. Different questions.
Preclinical · animal feeding study
Research note: Ishikawa · intact phosvitin in ratsAuthoritative review · nutrition and clinical context
Research note: NIH ODS · iron in contextAgency guidance · advertising substantiation
Research note: FTC · evidence behind health claims